Much depends on how the optimistic management commentary translates into revenues and earnings for Cipla. In line with its peers, Cipla Ltd’s shares have underperformed the benchmark indices over the last one year. From the looks of it, the March quarter (Q4 FY18) results provide no major reason to reverse this trend. This will further erode base business growth of existing players.” USFDA stands for the US Food and Drug Administration. Much depends on how the optimistic management commentary translates into revenues and earnings for Cipla.

Source: Mint May 23, 2018 03:22 UTC